Биография и факты
Основатель и гендиректор компании Oncobox, 29 лет, номинант в рейтинг 30 самых перспективных россиян до 30 лет по версии Forbes в 2020 году в категории «Наука и технологии».
Профиль Андрей Гаража — выпускник МФТИ и Калифорнийского технологического института, трудился в нескольких научных лабораториях, имеет опыт работы на венчурном рынке и в аналитике данных. Основал и возглавил компанию Oncobox, специализирующуюся на разработке персонализированных методов диагностики и лечения сложных случаев рака с применением оригинальных молекулярно-генетических методов и алгоритмов машинного обучения.
Бизнес Oncobox — первая российская биомедицинская компания, прошедшая акселерацию в главном инкубаторе Кремниевой долины Y Combinator. В совокупности стартап привлек около 280 млн рублей инвестиций, в том числе, от влиятельного фонда Khosla Ventures (инвестор GitLab, Impossible Foods и Square).
Наука За последние два года команда Oncobox опубликовала более 40 научных статей в ведущих журналах, включая Nature и Journal of Clinical Oncology, а также зарегистрировала патенты и клинические испытания, доказывающие эффективность тестов компании. На данный момент более 1500 пациентов прошли тестирование Oncobox.
Будущее В конце 2019 года Oncobox начала коммерческие продажи клиникам в России, Германии и США. На следующем этапе компания планирует новый раунд инвестиций (при участии международных инвесторов и РФПИ), клиническое исследование в Европе и мероприятия по включению теста в страховое покрытие, а также наращивание b2b-сегмента продаж большой «фарме» и другим исследовательским компаниям.
Научные интересы
Молекулярная биология, генетика, биоинформатика, психогенетика. Изучение транскрипционной активности мобильных элементов генома.
Все публикации
- Borisov N,
Sorokin M, Tkachev V, Garazha A,
Buzdin A (2020).
Cancer gene expression profiles associated with clinical outcomes to chemotherapy treatments. BMC Med Genomics 13 (Suppl 8), 111
-
Sorokin M, Ignatev K, Poddubskaya E,
Vladimirova U, Gaifullin N, Lantsov D, Garazha A, Allina D,
Suntsova M, Barbara V,
Buzdin A (2020).
RNA Sequencing in Comparison to Immunohistochemistry for Measuring Cancer Biomarkers in Breast Cancer and Lung Cancer Specimens. Biomedicines 8 (5),
- Zolotovskaia MA,
Sorokin MI, Petrov IV, Poddubskaya EV, Moiseev AA, Sekacheva MI, Borisov NM, Tkachev VS, Garazha AV, Kaprin AD, Shegay PV, Giese A, Kim E, Roumiantsev SA,
Buzdin AA (2020).
Disparity between Inter-Patient Molecular Heterogeneity and Repertoires of Target Drugs Used for Different Types of Cancer in Clinical Oncology. Int J Mol Sci 21 (5), 1–18
- Kim EL,
Sorokin M, Kantelhardt SR, Kalasauskas D, Sprang B, Fauss J, Ringel F, Garazha A, Albert E, Gaifullin N, Hartmann C, Naumann N, Bikar SE, Giese A,
Buzdin A (2020).
Intratumoral Heterogeneity and Longitudinal Changes in Gene Expression Predict Differential Drug Sensitivity in Newly Diagnosed and Recurrent Glioblastoma. Cancers (Basel) 12 (2),
-
Sorokin M, Poddubskaya E, Baranova M, Glusker A, Kogoniya L, Markarova E, Allina D,
Suntsova M, Tkachev V, Garazha A, Sekacheva M,
Buzdin A (2020).
RNA sequencing profiles and diagnostic signatures linked with response to ramucirumab in gastric cancer. Cold Spring Harb Mol Case Stud 6 (2),
- Tkachev V,
Sorokin M, Borisov C, Garazha A,
Buzdin A, Borisov N (2020).
Flexible Data Trimming Improves Performance of Global Machine Learning Methods in Omics-Based Personalized Oncology. Int J Mol Sci 21 (3),
- (книга) Tkachev V,
Sorokin M, Garazha A, Borisov N,
Buzdin A (2020).
Oncobox Method for Scoring Efficiencies of Anticancer Drugs Based on Gene Expression Data. Methods Mol Biol 2063, 235–255
- (книга) Zolotovskaia M,
Sorokin M, Garazha A, Borisov N,
Buzdin A (2020).
Molecular Pathway Analysis of Mutation Data for Biomarkers Discovery and Scoring of Target Cancer Drugs. Methods Mol Biol 2063, 207–234
- (книга) Borisov N,
Sorokin M, Garazha A,
Buzdin A (2020).
Quantitation of Molecular Pathway Activation Using RNA Sequencing Data. Methods Mol Biol 2063, 189–206
- (книга)
Nikitin D,
Sorokin M, Tkachev V, Garazha A, Markov A,
Buzdin A (2019).
RetroSpect, a new method of measuring gene regulatory evolution rates using co-mapping of genomic functional features with transposable elements. Evolution, Origin of Life, Concepts and Methods , 85–111
-
Buzdin A,
Sorokin M, Garazha A, Glusker A, Aleshin A, Poddubskaya E, Sekacheva M, Kim E, Gaifullin N, Giese A, Seryakov A, Rumiantsev P, Moshkovskii S, Moiseev A (2019).
RNA sequencing for research and diagnostics in clinical oncology. Semin Cancer Biol 60, 311–323
- Nikitin D, Garazha A,
Sorokin M, Penzar D, Tkachev V, Markov A, Gaifullin N, Borger P, Poltorak A,
Buzdin A (2019).
Correction: Nikitin, D., et al. Retroelement-Linked Transcription Factor Binding Patterns Point to Quickly Developing Molecular Pathways in Human Evolution. 2019, , 130. Cells 8 (8),
-
Suntsova M, Gaifullin N, Allina D, Reshetun A, Li X, Mendeleeva L, Surin V, Sergeeva A, Spirin P, Prassolov V, Morgan A, Garazha A,
Sorokin M,
Buzdin A (2019).
Atlas of RNA sequencing profiles for normal human tissues. Sci Data 6 (1), 36
- Borisov N, Shabalina I, Tkachev V,
Sorokin M, Garazha A, Pulin A, Eremin II,
Buzdin A (2019).
Shambhala: a platform-agnostic data harmonizer for gene expression data. BMC Bioinformatics 20 (1), 66
- Nikitin D, Garazha A,
Sorokin M, Penzar D, Tkachev V, Markov A, Gaifullin N, Borger P, Poltorak A,
Buzdin A (2019).
Retroelement-Linked Transcription Factor Binding Patterns Point to Quickly Developing Molecular Pathways in Human Evolution. Cells 8 (2), 130
- Zolotovskaia MA,
Sorokin MI,
Emelianova AA, Borisov NM,
Kuzmin DV, Borger P, Garazha AV,
Buzdin AA (2019).
Pathway Based Analysis of Mutation Data Is Efficient for Scoring Target Cancer Drugs. Front Pharmacol 10 (JAN), 1
- Tkachev V,
Sorokin M, Mescheryakov A, Simonov A, Garazha A,
Buzdin A, Muchnik I, Borisov N (2019).
FLOating-Window Projective Separator (FloWPS): A Data Trimming Tool for Support Vector Machines (SVM) to Improve Robustness of the Classifier. Front Genet 9 (JAN), 717
-
Sorokin M,
Kholodenko R,
Suntsova M, Malakhova G, Garazha A,
Kholodenko I, Poddubskaya E, Lantsov D, Stilidi I, Arhiri P, Osipov A,
Buzdin A (2018).
Oncobox bioinformatical platform for selecting potentially effective combinations of target cancer drugs using high-throughput gene expression data. Cancers (Basel) 10 (10),
-
Buzdin A,
Sorokin M, Garazha A, Sekacheva M, Kim E, Zhukov N, Wang Y, Li X, Kar S, Hartmann C, Samii A, Giese A, Borisov N (2018).
Molecular pathway activation – New type of biomarkers for tumor morphology and personalized selection of target drugs. Semin Cancer Biol 53, 110–124
- Nikitin D, Penzar D, Garazha A,
Sorokin M, Tkachev V, Borisov N, Poltorak A, Prassolov V,
Buzdin AA (2018).
Profiling of human molecular pathways affected by retrotransposons at the level of regulation by transcription factor proteins. Front Immunol 9 (JAN), 30
-
Sorokin M,
Kholodenko R, Grekhova A,
Suntsova M, Pustovalova M, Vorobyeva N,
Kholodenko I, Malakhova G, Garazha A, Nedoluzhko A, Vasilov R, Poddubskaya E, Kovalchuk O, Adamyan L, Prassolov V, Allina D,
Kuzmin D, Ignatev K, Osipov A,
Buzdin A (2017).
Acquired resistance to tyrosine kinase inhibitors may be linked with the decreased sensitivity to X-ray irradiation. Oncotarget 9 (4), 5111–5124
- Borisov N,
Suntsova M,
Sorokin M, Garazha A, Kovalchuk O, Aliper A,
Ilnitskaya E, Lezhnina K, Korzinkin M, Tkachev V, Saenko V, Saenko Y, Sokov DG, Gaifullin NM, Kashintsev K, Shirokorad V, Shabalina I, Zhavoronkov A, Mishra B, Cantor CR,
Buzdin A (2017).
Data aggregation at the level of molecular pathways improves stability of experimental transcriptomic and proteomic data. Cell Cycle 16 (19), 1810–1823
-
Buzdin AA, Prassolov V, Garazha AV (2017).
Friends-Enemies: Endogenous retroviruses are major transcriptional regulators of human DNA. Front Chem 5 (JUN), 35
- (книга) Garazha A,
Suntsova M,
Buzdin A (2017).
Structural and functional coevolution of human endogenous retroviruses with our genome. , 479–485
- Petrov I,
Suntsova M,
Ilnitskaya E, Roumiantsev S,
Sorokin M, Garazha A, Spirin P, Lebedev T, Gaifullin N, Larin S, Kovalchuk O, Konovalov D, Prassolov V, Roumiantsev A,
Buzdin A (2017).
Gene expression and molecular pathway activation signatures of MYCN-amplified neuroblastomas. Oncotarget 8 (48), 83768–83780
-
Buzdin AA, Artcibasova AV, Fedorova NF,
Suntsova MV, Garazha AV,
Sorokin MI, Allina D, Shalatonin M, Borisov NM, Zhavoronkov AA, Kovalchuk I, Kovalchuk O, Kushch AA (2016).
Early stage of cytomegalovirus infection suppresses host microRNA expression regulation in human fibroblasts. Cell Cycle 15 (24), 3378–3389
- Aliper A, Belikov AV, Garazha A, Jellen L, Artemov A,
Suntsova M, Ivanova A, Venkova L, Borisov N,
Buzdin A, Mamoshina P, Putin E, Swick AG, Moskalev A, Zhavoronkov A (2016).
In search for geroprotectors: In silico screening and in vitro validation of signalome-level mimetics of young healthy state. Aging (Albany NY) 8 (9), 2127–2152
- Petrov I,
Suntsova M, Mutorova O,
Sorokin M, Garazha A,
Ilnitskaya E, Spirin P, Larin S, Zhavoronkov A, Kovalchuk O, Prassolov V, Roumiantsev A,
Buzdin A (2016).
Molecular pathway activation features of pediatric acute myeloid leukemia (AML) and acute lymphoblast leukemia (ALL) cells. Aging (Albany NY) 8 (11), 2936–2947
-
Suntsova M, Garazha A, Ivanova A, Kaminsky D, Zhavoronkov A,
Buzdin A (2015).
Molecular functions of human endogenous retroviruses in health and disease. Cell Mol Life Sci 72 (19), 3653–3675
- Moskalev A, Chernyagina E, de Magalhães JP, Barardo D, Thoppil H, Shaposhnikov M, Budovsky A, Fraifeld VE, Garazha A, Tsvetkov V, Bronovitsky E, Bogomolov V, Scerbacov A, Kuryan O, Gurinovich R, Jellen LC, Kennedy B, Mamoshina P, Dobrovolskaya E, Aliper A, Kaminsky D, Zhavoronkov A (2015).
Geroprotectors.org: A new, structured and curated database of current therapeutic interventions in aging and age-related disease. Aging (Albany NY) 7 (9), 616–628
- Garazha A, Ivanova A,
Suntsova M, Malakhova G, Roumiantsev S, Zhavoronkov A,
Buzdin A (2015).
New bioinformatic tool for quick identification of functionally relevant endogenous retroviral inserts in human genome. Cell Cycle 14 (9), 1476–1484
- Spirin PV, Lebedev TD,
Orlova NN, Gornostaeva AS, Prokofjeva MM, Nikitenko NA, Dmitriev SE,
Buzdin AA, Borisov NM, Aliper AM, Garazha AV, Rubtsov PM, Stocking C, Prassolov VS (2014).
Silencing AML1-ETO gene expression leads to simultaneous activation of both pro-apoptotic and proliferation signaling. Leukemia 28 (11), 2222–2228
- Zhavoronkov A,
Buzdin AA, Garazha AV, Borisov NM, Moskalev AA (2014).
Signaling pathway cloud regulation for in silico screening and ranking of the potential geroprotective drugs. Front Genet 5 (MAR), 49
-
Zabolotneva AA, Zhavoronkov AA, Shegay PV, Gaifullin NM, Alekseev BY, Roumiantsev SA, Garazha AV, Kovalchuk O, Aravin A,
Buzdin AA (2013).
A systematic experimental evaluation of microRNA markers of human bladder cancer. Front Genet 4 (NOV), 247
-
Suntsova M, Gogvadze EV, Salozhin S, Gaifullin N,
Eroshkin F, Dmitriev SE,
Martynova N, Kulikov K, Malakhova G, Tukhbatova G, Bolshakov AP, Ghilarov D, Garazha A, Aliper A, Cantor CR, Solokhin Y, Roumiantsev S, Balaban P, Zhavoronkov A,
Buzdin A (2013).
Human-specific endogenous retroviral insert serves as an enhancer for the schizophrenia-linked gene PRODH. Proc Natl Acad Sci U S A 110 (48), 19472–19477
-
Zabolotneva AA, Zhavoronkov A, Garazha AV, Roumiantsev SA,
Buzdin AA (2013).
Characteristic patterns of microrna expression in human bladder cancer. Front Genet 3 (JAN), 310
- Baskaev K, Garazha A, Gaifullin N,
Suntsova MV,
Zabolotneva AA,
Buzdin AA (2012).
NMETR: Technique for facile recovery of hypomethylation genomic tags. Gene 498 (1), 75–80